Alder Biopharmaceuticals (NASDAQ:ALDR) had its price objective lowered by Canaccord Genuity from $21.00 to $20.00 in a research note issued to investors on Thursday morning. Canaccord Genuity currently has a buy rating on the biopharmaceutical company’s stock.

ALDR has been the subject of a number of other research reports. Cantor Fitzgerald reissued a hold rating and issued a $14.00 price target on shares of Alder Biopharmaceuticals in a report on Tuesday, February 26th. Zacks Investment Research raised Alder Biopharmaceuticals from a hold rating to a buy rating and set a $15.00 price target for the company in a report on Tuesday, February 12th. BidaskClub raised Alder Biopharmaceuticals from a sell rating to a hold rating in a report on Thursday, January 17th. Mizuho reissued a hold rating and issued a $15.00 price target on shares of Alder Biopharmaceuticals in a report on Wednesday, December 12th. Finally, Credit Suisse Group set a $17.00 price target on Alder Biopharmaceuticals and gave the company a hold rating in a report on Thursday, December 13th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the stock. Alder Biopharmaceuticals currently has a consensus rating of Hold and an average target price of $20.75.

Shares of ALDR stock traded down $0.14 during trading hours on Thursday, reaching $13.44. The company had a trading volume of 3,496 shares, compared to its average volume of 1,175,109. The company has a debt-to-equity ratio of 1.66, a quick ratio of 14.87 and a current ratio of 14.87. Alder Biopharmaceuticals has a twelve month low of $9.44 and a twelve month high of $20.87. The firm has a market cap of $930.23 million, a P/E ratio of -2.77 and a beta of 2.80.

Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc lifted its holdings in Alder Biopharmaceuticals by 2.3% during the 3rd quarter. Vanguard Group Inc now owns 5,154,209 shares of the biopharmaceutical company’s stock worth $85,817,000 after buying an additional 115,375 shares during the last quarter. Artal Group S.A. acquired a new stake in shares of Alder Biopharmaceuticals during the 4th quarter worth approximately $2,050,000. Assenagon Asset Management S.A. acquired a new stake in shares of Alder Biopharmaceuticals during the 4th quarter worth approximately $614,000. Bellevue Group AG raised its position in shares of Alder Biopharmaceuticals by 19.3% during the 3rd quarter. Bellevue Group AG now owns 905,254 shares of the biopharmaceutical company’s stock worth $15,072,000 after purchasing an additional 146,290 shares during the period. Finally, TIAA CREF Investment Management LLC raised its position in shares of Alder Biopharmaceuticals by 748.3% during the 3rd quarter. TIAA CREF Investment Management LLC now owns 1,049,133 shares of the biopharmaceutical company’s stock worth $17,468,000 after purchasing an additional 925,463 shares during the period.

Alder Biopharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, Australia, and Ireland.

Featured Story: Outstanding Shares, Buying and Selling Stocks

Analyst Recommendations for Alder Biopharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.